Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Nature of Business and Liquidity (Details Textual)

v3.24.2.u1
Note 1 - Nature of Business and Liquidity (Details Textual) - USD ($)
Aug. 12, 2024
Aug. 05, 2024
Jun. 30, 2024
Dec. 31, 2023
Retained Earnings (Accumulated Deficit)     $ (63,562,752) $ (60,206,217)
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Subsequent Event [Member]        
Stockholders' Equity, Reverse Stock Split 5 5